TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25503163

Group type: EXPERIMENTAL
Intervention: S‐1 plus lafutidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: S‐1
Number of subjects: 0
Study: 22583583

Group type: EXPERIMENTAL
Intervention: Early rebonding with round bur for adhesive removal
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Delayed rebonding with tungsten carbide bur for adhesive removal
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Delayed rebonding with green rubber wheel for adhesive removal
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Delayed rebonding after one month in a simulated oral environment
Number of subjects: 68
Study: 20869557

Group type: EXPERIMENTAL
Intervention: 0.3 percent foam‐based ciprofloxacin (FoamOtic Cipro)
Number of subjects: 63

Group type: COMPARATOR
Intervention: 0.3 percent solution‐based ciprofloxacin (Ciloxan)
Number of subjects: 63
Study: 18251035

Group type: EXPERIMENTAL
Intervention: Web‐based learning module (WM)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Small group PRM instruction (SG)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Standard classroom instruction (CI)
Number of subjects: 3
Study: 15851401

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (daily antioxidant powder containing riboflavin, vitamin E, selenium, and N-acetylcysteine for 20 weeks)
Number of subjects: 2332

Group type: COMPARATOR
Intervention: Placebo (for 20 weeks)
Number of subjects: 2332

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 2332

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2332
Study: 12844385

Group type: EXPERIMENTAL
Intervention: Fish-oil capsules containing 400 mg DHA/g (200 mg/d) (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo containing 810 mg oleic acid/g (400 mg/d) (n=50)
Number of subjects: 100
Study: 11077510

Group type: EXPERIMENTAL
Intervention: Reduced intake of saturated fat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intake of fish, fish oils, and alpha-linolenic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Folic acid, vitamin B6, and B12
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intake of nuts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plant sterols and psyllium
Number of subjects: 0
Study: 8783998

Group type: EXPERIMENTAL
Intervention: Direct infusion of shed mediastinal blood (Group I)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Not infusing shed mediastinal blood (Group II)
Number of subjects: 40
Study: 1536437

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 45
Study: 6539812

Group type: EXPERIMENTAL
Intervention: Metoclopramide (2 mg/kg intravenous every two hours for five doses)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Haloperidol (3 mg intravenous every two hours for five doses)
Number of subjects: 28
Study: 30615646

Group type: EXPERIMENTAL
Intervention: Iron with folic acid supplementation (IFAS)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: IFAS counseling
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Knowledge about IFAS
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Gravidity
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Gestational age at first ANC visit
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Advice about IFAS
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Current anemia
Number of subjects: 262
Study: 29199384

Group type: EXPERIMENTAL
Intervention: LED therapy (658 nm) with 40 mW, 7 J/cm2 on every other day
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (contralateral limb)
Number of subjects: 5
Study: 26760085

Group type: EXPERIMENTAL
Intervention: Low-cost mesh
Number of subjects: 302

Group type: COMPARATOR
Intervention: Commercial mesh
Number of subjects: 302
Study: 26050706

Group type: EXPERIMENTAL
Intervention: 600 mg oral N-acetylcysteine (NAC) twice daily during AmB treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 22275504

Group type: EXPERIMENTAL
Intervention: Autologous CIK cell immunotherapy
Number of subjects: 148

Group type: COMPARATOR
Intervention: Interleukin-2 treatment combination with IFN-α-2a
Number of subjects: 148
Study: 20637967

Group type: EXPERIMENTAL
Intervention: 21-mg/24-hour patch
Number of subjects: 50

Group type: COMPARATOR
Intervention: 25-mg/16-hour patch
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 21-mg/24-hour patch (16-hour application time)
Number of subjects: 50
Study: 18341602

Group type: EXPERIMENTAL
Intervention: OFD + 24% EDTA conditioning + EMD application
Number of subjects: 15

Group type: COMPARATOR
Intervention: OFD + 24% EDTA conditioning
Number of subjects: 15
Study: 16466061

Group type: EXPERIMENTAL
Intervention: Oral zinc sulphate (50 mg of elemental zinc)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 14675012

Group type: EXPERIMENTAL
Intervention: ICD programmed to a lower limit of VT detection at 128 beats/min (group I, n = 44)
Number of subjects: 90

Group type: COMPARATOR
Intervention: ICD programmed to a lower limit of VT detection at 153 beats/min (group II, n = 46)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Algorithm for tachycardias <153 beats/min
Number of subjects: 90
Study: 10616135

Group type: EXPERIMENTAL
Intervention: Embase standard searches (index terms only)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medline standard searches (index terms only)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PsycINFO standard searches (index terms only)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Embase expert searches (index and free text terms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medline expert searches (index and free text terms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PsycINFO expert searches (index and free text terms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medline
Number of subjects: 0
Study: 8693439

Group type: EXPERIMENTAL
Intervention: Exercise challenge with dry air (8 minutes of cycle exercise at 60% maximum voluntary ventilation)
Number of subjects: 109
Study: 1988516

Group type: EXPERIMENTAL
Intervention: Ampicillin (Amp)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP/SMZ)
Number of subjects: 85
Study: 6325720

Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29533260

Group type: EXPERIMENTAL
Intervention: Aron Alpha A adhesive applied at 2 sites along the catheter with film dressing
Number of subjects: 55

Group type: COMPARATOR
Intervention: Film dressing alone (Control)
Number of subjects: 55
Study: 29675792

Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 955

Group type: COMPARATOR
Intervention: No maintenance
Number of subjects: 955
Study: 27097785

Group type: EXPERIMENTAL
Intervention: High load lifting exercise
Number of subjects: 70

Group type: COMPARATOR
Intervention: Low load motor control exercises
Number of subjects: 70
Study: 22952213

Group type: EXPERIMENTAL
Intervention: Darexaban 15 mg bid
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Darexaban 30 mg bid
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 19827464

Group type: EXPERIMENTAL
Intervention: 6.4% maltodextrin solution (CHO)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Water (PLA)
Number of subjects: 14
Study: 15637686

Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen (PSA) screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12611212

Group type: EXPERIMENTAL
Intervention: Ministernotomy approach (group Gm)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard total sternotomy approach (group Gs)
Number of subjects: 98
Study: 9413354

Group type: EXPERIMENTAL
Intervention: Eflornithine (0.5 to 3 g/m2 daily for 6 to 12 months in phase 1; 0.5 g/m2 for 12 months in phase 2)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 8189347

Group type: EXPERIMENTAL
Intervention: High status in-group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low status in-group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative in-group size
Number of subjects: 0
Study: 3555956

Group type: EXPERIMENTAL
Intervention: Velosulin/Insulatard
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Semi-synthetic human insulin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Treatment periods in chronological order
Number of subjects: 12

Group type: COMPARATOR
Intervention: All regimens
Number of subjects: 12
Study: 30666366

Group type: EXPERIMENTAL
Intervention: SOMS-guided mobility treatment with a facilitator
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 200
Study: 30541536

Group type: EXPERIMENTAL
Intervention: e-IMR + IMR
Number of subjects: 60

Group type: COMPARATOR
Intervention: IMR only
Number of subjects: 60
Study: 26863870

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 36
Study: 24606242

Group type: EXPERIMENTAL
Intervention: NoRx (open-label 'no treatment')
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (patient-blinded)
Number of subjects: 21
Study: 23272490

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized house dust mite extract
Number of subjects: 157
Study: 20873892

Group type: EXPERIMENTAL
Intervention: Gender-specific biannual personalized normative feedback (PNF)
Number of subjects: 818

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 818
Study: 18187431

Group type: EXPERIMENTAL
Intervention: Glucomannan (Propol) 2 x 1.3 gr daily for two months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo powder daily for two months
Number of subjects: 48
Study: 15210522

Group type: EXPERIMENTAL
Intervention: Embryonic tissue implants
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham operation (placebo)
Number of subjects: 40
Study: 11454015

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (GF), 600 mg b.i.d. for 12 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9683392

Group type: EXPERIMENTAL
Intervention: Cereals fortified with 200 microg of folic acid per portion
Number of subjects: 119

Group type: COMPARATOR
Intervention: Unfortified cereals
Number of subjects: 119
Study: 7823273

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration with metronidazole gel (25%, 250 mg/g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Guided tissue regeneration without metronidazole gel (control)
Number of subjects: 12
Study: 2898321

Group type: EXPERIMENTAL
Intervention: 15 mg metaclazepam per day for 13 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: 4 mg bromazepam per day for 13 days
Number of subjects: 50
Study: 30133674

Group type: EXPERIMENTAL
Intervention: Minimally invasive laparoscopic esophagectomy (EMIL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open trans-hiatal esophagectomy (ETHA)
Number of subjects: 30
Study: 28348155

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Number of subjects: 781

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 781
Study: 26084366

Group type: EXPERIMENTAL
Intervention: Prenatal iron plus folic acid supplementation
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: Multimicronutrient supplementation
Number of subjects: 1744

Group type: COMPARATOR
Intervention: Prenatal folic acid supplementation
Number of subjects: 1744
Study: 24140602

Group type: EXPERIMENTAL
Intervention: SHD-RU486 group
Number of subjects: 90

Group type: COMPARATOR
Intervention: RU486 group
Number of subjects: 90
Study: 21316208

Group type: EXPERIMENTAL
Intervention: DHA (220 mg/day)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: DHA+AA (220 mg/day)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 18494204

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Physical therapy in open cholecystectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 100
Study: 17159063

Group type: EXPERIMENTAL
Intervention: CRT-defibrillator therapy
Number of subjects: 1520

Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 1520

Group type: EXPERIMENTAL
Intervention: CRT therapy
Number of subjects: 1520

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction >20%
Number of subjects: 1520

Group type: EXPERIMENTAL
Intervention: QRS duration >160 ms
Number of subjects: 1520

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1520

Group type: EXPERIMENTAL
Intervention: Advanced NYHA class IV heart failure
Number of subjects: 1520

Group type: EXPERIMENTAL
Intervention: Renal dysfunction
Number of subjects: 1520

Group type: EXPERIMENTAL
Intervention: Female gender in CRT-defibrillator patients
Number of subjects: 1520

Group type: EXPERIMENTAL
Intervention: Use of neurohormonal antagonists
Number of subjects: 1520

Group type: EXPERIMENTAL
Intervention: Class IV heart failure status
Number of subjects: 1520

Group type: EXPERIMENTAL
Intervention: Appropriate ICD therapy
Number of subjects: 1520
Study: 12751941

Group type: EXPERIMENTAL
Intervention: Open surgical technique (n=38)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Minimally invasive technique (n=35)
Number of subjects: 73
Study: 10803456

Group type: EXPERIMENTAL
Intervention: Gabapentin, Lamotrigine, Tiagabine, Vigabatrin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felbamate, Oxcarbazepine, Topiramate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 0
Study: 9552819

Group type: EXPERIMENTAL
Intervention: All Bond 2 (AB2) + Z‐100 composite
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Scotchbond Multipurpose Plus (SMPP) + Z‐100
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: AB2 in conjunction with Bisfil 2B as liner and Z‐100
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study: 8459990

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg i.v. 0, 4 and 8 h following chemotherapy)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Metoclopramide (3 mg/kg i.v. followed by an infusion of 0.5 mg/kg/h for 8 h)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg) with dexamethasone (16 mg) before chemotherapy followed by oral dosing with 8 mg ondansetron 3 times daily for 5 days
Number of subjects: 2

Group type: COMPARATOR
Intervention: Metoclopramide (60 mg) with dexamethasone (16 mg) before chemotherapy followed by oral dosing with 20 mg metoclopramide 3 times daily for 5 days
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg) given orally twice daily
Number of subjects: 2
Study: 3816928

Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone 1 g
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intraperitoneal ceftriaxone 1 g
Number of subjects: 8
Study: 31204873

Group type: EXPERIMENTAL
Intervention: Experimental biopsy group (6 anterior cores + 6 posterior cores)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Standard biopsy group (12 posterior cores)
Number of subjects: 340
Study: 29684990

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES) infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: 5% albumin infusion
Number of subjects: 40
Study: 26880105

Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 99

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 99
Study: 24492945

Group type: EXPERIMENTAL
Intervention: GM‐CSF
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 22614886

Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy (ART) initiated before 3 months of age
Number of subjects: 90

Group type: COMPARATOR
Intervention: Deferred antiretroviral therapy (ART)
Number of subjects: 90
Study: 20653225

Group type: EXPERIMENTAL
Intervention: Auditory occasion setter (screeching brakes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abstract auditory warning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Environmental auditory warning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Speech message
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual display
Number of subjects: 0

Group type: COMPARATOR
Intervention: No warning
Number of subjects: 0
Study: 18796142

Group type: EXPERIMENTAL
Intervention: Artemether/lumefantrine
Number of subjects: 97

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil
Number of subjects: 97
Study: 16096242

Group type: EXPERIMENTAL
Intervention: Community-based brain injury rehabilitation service
Number of subjects: 1492

Group type: EXPERIMENTAL
Intervention: Taxonomy for goal classification
Number of subjects: 1492
Study: 11836563

Group type: EXPERIMENTAL
Intervention: 5'-DFUR treatment for 6 months
Number of subjects: 1217

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1217
Study: 10626529

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 61

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 61
Study: 8677154

Group type: EXPERIMENTAL
Intervention: Plasma antioxidant activity (AOA) during clinical treatment (induction of chemotherapy, surgery, radiotherapy, maintenance chemotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceruloplasmin levels in children with malignancy
Number of subjects: 0
Study: 2186259

Group type: EXPERIMENTAL
Intervention: Veramex 80 (80 mg non-retarded Verapamil)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference substance (80 mg non-retarded Verapamil)
Number of subjects: 18
Study: 386125

Group type: EXPERIMENTAL
Intervention: Cimetidine, 1 g daily over eight weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31606042

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stretching exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stretching exercises alone
Number of subjects: 0
Study: 28124478

Group type: EXPERIMENTAL
Intervention: Rifapentine (1200 mg daily)
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: Rifapentine
Number of subjects: 657

Group type: COMPARATOR
Intervention: Rifampin
Number of subjects: 657
Study: 25712967

Group type: EXPERIMENTAL
Intervention: 15-μg dose of A/H5N1/Indonesia/05/05 (clade 2) vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 90-μg dose of A/H5N1/Indonesia/05/05 (clade 2) vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose priming with mismatched pandemic influenza A(H5N1) vaccine
Number of subjects: 0
Study: 23741965

Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 41
Study: 20192708

Group type: EXPERIMENTAL
Intervention: Hormone treatment with drospirenone 2 mg + estradiol emidrate 1 mg for 6 months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 23
Study: 18987654

Group type: EXPERIMENTAL
Intervention: TPMT wild type
Number of subjects: 601

Group type: COMPARATOR
Intervention: TPMT low activity group (heterozygous and deficient)
Number of subjects: 601
Study: 17854239

Group type: EXPERIMENTAL
Intervention: Longer time to all-cause treatment discontinuation
Number of subjects: 1627

Group type: EXPERIMENTAL
Intervention: Completers of trials (761 patients)
Number of subjects: 1627

Group type: EXPERIMENTAL
Intervention: Greater symptom improvement
Number of subjects: 1627
Study: 15491558

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (800 mcg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (800 mcg)
Number of subjects: 200
Study: 12067152

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normobaric oxygen (O2)
Number of subjects: 6
Study: 9246650

Group type: EXPERIMENTAL
Intervention: Affect-management treatment group (n = 17)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Wait list control condition (n = 16)
Number of subjects: 48
Study: 8297916

Group type: EXPERIMENTAL
Intervention: FeSO4 (60 or 120 mg Fe/d)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 447
Study: 2436092

Group type: EXPERIMENTAL
Intervention: Amitriptyline (up to 150 mg nightly)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 29
Study: 2688081

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg
Number of subjects: 1630

Group type: COMPARATOR
Intervention: Piroxicam 20 mg
Number of subjects: 1630

Group type: COMPARATOR
Intervention: Diclofenac sodium retard 100 mg
Number of subjects: 1630

Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 1630
Study: 31025412

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 14
Study: 28809624

Group type: EXPERIMENTAL
Intervention: Hyperextension brace (HB)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Custom-made semirigid orthosis (SO)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Custom-made rigid orthosis (RO)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SF-12 Health Survey
Number of subjects: 12
Study: 25323621

Group type: EXPERIMENTAL
Intervention: Aztreonam for inhalation solution (AZLI)
Number of subjects: 542

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Respiratory Symptoms scale
Number of subjects: 542
Study: 23229461

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 22
Study: 21537338

Group type: EXPERIMENTAL
Intervention: Gait training on a treadmill with body weight support (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional gait training and physiotherapy (group B)
Number of subjects: 30
Study: 19351876

Group type: EXPERIMENTAL
Intervention: valsartan treatment for 90 days
Number of subjects: 3194
Study: 17168667

Group type: EXPERIMENTAL
Intervention: Efamol® evening primrose oil (EPO)
Number of subjects: 1207